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• Background:  
 
The prostate is normally a walnut-sized gland located just below the urinary bladder.  
The prostate encircles the neck of the bladder, thus it can affect urine flow.   Benign 
prostatic hyperplasia (BPH) may cause prostatic enlargement and subsequently 
compression of the urethra and can cause urinary obstruction.  BPH is of clinical 
significance when men experience bothersome lower urinary tract symptoms (LUTS).  
LUTS can cause distress and negatively impact on quality of life (QOL) thus requiring 
treatment and intervention. 
 
Shared treatment decisions are based upon the level of distress, bother, severity and 
burden of LUTS on the patients QOL. Initial treatment options for BPH include 
conservative management (watchful waiting and lifestyle modification) and 
medications (alpha-blockers and 5-alpha reductase inhibitors).  However, if patients 
experience complications such as acute urinary retention, recurrent urinary tract 
infection, bladder stones or diverticula, haematuria, or renal insufficiency or don’t 
respond to medical treatment then surgical options are considered.  Clinical 
guidelines recommend monopolar or bipolar transurethral resection of the prostate 
(TURP) as the first line surgical approach. It is regarded as an effective form of 
treatment that all urologists are trained to perform. However, TURP can cause 
complications, such as bleeding, urinary tract infections, bladder neck contracture, 
erectile dysfunction and retrograde ejaculation (more than 50% of patients). It can 
also in rare instances cause dilutional hyponatraemia (known as TUR syndrome). To 
avoid these issues, newer minimally invasive surgical alternatives are being 
developed and starting to be used in practice, such as Aquablation.  Aquablation is a 
minimally invasive water ablation therapy which combines image guidance and 
robotics for the removal of benign prostatic tissue.  However, it is unclear if 
Aquablation translates to similar or improved clinical outcomes with fewer 
complications compared to traditional surgical approaches. 
 
• Objective/s:  
 
The overall aim was to assess the effectiveness of Aquablation for the treatment of 
lower urinary tract symptoms in men with BPH. The primary outcomes were urologic 
scores, QoL and major adverse events (Hwang et al 2019). Other outcomes of 
interest were retreatments, erectile function and ejaculatory dysfunction.  
 
Participants in parallel group randomised controlled trials, cluster-randomised trials 
and prospective cohort studies with concurrent comparison groups were men (age 
over 40) diagnosed with BPH (prostate volume of 20mL or greater, International 
Prostate Symptom Scores (IPSS) of eight or over, maximum flow rate of less than 
15mL/second). Studies eligible for inclusion used either chance to decide how men 
were treated or studies where the urologist determined the treatment. Studies 
compared Aquablation (experimental intervention) with other procedures to manage 
urinary symptoms caused by an enlarged prostate up to 12 months of follow up or 
less.  
 
• Intervention/Methods:  
 
Aquablation is a minimally invasive therapy using water ablation in combination with 
image guidance and robotics for the removal of prostatic tissue. This therapy delivers 
a high-pressure water jet, which can ablate the adenomatous tissue whilst preserving 
collagenous structures such as the surgical capsule, bladder neck and blood vessels.  
 
Comparisons of Aquablation against sham control or no intervention, transurethral 
resection of the prostate (TURP), laser ablations or enucleations of the prostate, 
prostatic urethral lift, convective radiofrequency, other minimally invasive therapies or 
simple prostatectomy were the focus. The researchers sought to determine whether 
Aquablation was more effective up to 12 months follow up than other interventions 
through mean changes from baseline or final mean value in urologic symptom scores 




One single multicentre (17 centers) and multicountry (Australia 1, New Zealand 1,UK 
3 and USA 12 all classed as high income countries) RCT was included. A total of 184 
participants (of which 168 were white) were involved in this RCT which was 
sponsored by the device manufacturer.   
 
This study compared Aquablation to TURP to 12 months follow up. Change in IPSS 
were measured at baseline, I month, 3 months, 6 months and 12 months. Overall the 
reviewers found that Aquablation probably has similar results to TURP for urological 
scores and may improve QoL. The evidence is uncertain about impact on the risk of 
adverse events. Aquablation (up to 12 months) may offer similar rates of retreatment, 
erectile and ejaculatory dysfunction to TURP but the evidence is very uncertain. The 
authors state there may be a small benefit to sexually active men in ejaculatory 
function but this is uncertain. The study was not designed to assess subgroup effects 
so the limited evidence that Aquablation may improve urologic symptom scores in 




The authors of this review conclude that the effects of Aquablation over TURP on 
urologic symptom scores are probably similar, and QoL may be similar at 12 months. 
The reviewers were unable to measure adverse events with concerns over 
imprecision and selective reporting bias and therefore it is very uncertain whether 
these are similar. The one included RCT was judged to be moderate to very low 
certainty evidence depending on the outcome although 12 months is quite a short 
follow up period. The reviewers identified that patients and clinicians making 
decisions about treatment options needs to be aware that the evidence for 
Aquablation is drawn from a single, relatively small RCT supported by the device 
maker.  The present evidence does not support the use of Aquablation to other 
treatment forms in men with lower urinary tract symptoms due to BPH. More rigorous 
and transparently reported research is required as the current evidence base offers 
little guidance for nurses as to alternative effective interventions for BPH. Future 
research should compare Aquablation to a range of treatment forms alongside the 
collection of longer-term data. Overall certainty about the evidence in this review 
ranged from moderate to very low however, the high degree of uncertainty with 
regard to harm means we can have little confidence in these results for clinical 
decision-making.   
 
• Implications for Practice:  
 
BPH is a common condition in men over the age of 50 years old.  BPH can cause 
debilitating and distressing LUTS which can profoundly affect QOL.  Nurses can 
support patients by developing shared self-management care plans, particularly 
around the conservative management options, including lifestyle modifications (i.e 
caffeine reduction, bladder retraining, fluid intake, bowel habits, pelvic floor 
exercises, and smoking cessation) and patient education and counselling for 
medications (alpha-blockers and 5-alpha reductase inhibitors).  However, for patients 
who require surgical intervention for the treatment of BPH this review has several 
important considerations for nursing practice.   
 
Given the dearth of research which compared Aquablation to traditional surgical 
approaches for BPH we are not clear about the benefits or indeed the potential 
harms of this new minimally invasive surgical approach.  Nurses are fully embedded 
in the multidisciplinary team and can be involved in supporting treatment decisions 
for the clinical management of BPH, and co-ordinate referrals to their urologists for 
consideration of surgical intervention for patients.   Nurses should clearly explain that 
there is a lack of robust empirical evidence to recommend Aquablation at this time 
compared to traditional surgical techniques.    
 
Internationally, given the different funding models within healthcare systems patients 
may also be at risk of financial toxicity in relation to Aquablation.  Nurses should be 
aware of this significant issue that may impact upon patients.  Based upon the results 
of one study, at this time nurses are unable to recommend this treatment as 
evidence-based practice for patients affected by BPH in our care.  
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